331 related articles for article (PubMed ID: 26527801)
1. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance.
Palmer DC; Guittard GC; Franco Z; Crompton JG; Eil RL; Patel SJ; Ji Y; Van Panhuys N; Klebanoff CA; Sukumar M; Clever D; Chichura A; Roychoudhuri R; Varma R; Wang E; Gattinoni L; Marincola FM; Balagopalan L; Samelson LE; Restifo NP
J Exp Med; 2015 Nov; 212(12):2095-113. PubMed ID: 26527801
[TBL] [Abstract][Full Text] [Related]
2. The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8
Guittard G; Dios-Esponera A; Palmer DC; Akpan I; Barr VA; Manna A; Restifo NP; Samelson LE
Sci Rep; 2018 Mar; 8(1):5336. PubMed ID: 29593227
[TBL] [Abstract][Full Text] [Related]
3. SOCS-1 regulates IL-15-driven homeostatic proliferation of antigen-naive CD8 T cells, limiting their autoimmune potential.
Davey GM; Starr R; Cornish AL; Burghardt JT; Alexander WS; Carbone FR; Surh CD; Heath WR
J Exp Med; 2005 Oct; 202(8):1099-108. PubMed ID: 16216888
[TBL] [Abstract][Full Text] [Related]
4. Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.
Tucker CG; Mitchell JS; Martinov T; Burbach BJ; Beura LK; Wilson JC; Dwyer AJ; Singh LM; Mescher MF; Fife BT
J Immunol; 2020 Sep; 205(5):1449-1460. PubMed ID: 32737148
[TBL] [Abstract][Full Text] [Related]
5. Blocking TCR restimulation induced necroptosis in adoptively transferred T cells improves tumor control.
Kesarwani P; Chakraborty P; Gudi R; Chatterjee S; Scurti G; Toth K; Simms P; Husain M; Armeson K; Husain S; Garrett-Mayer E; Vasu C; Nishimura MI; Mehrotra S
Oncotarget; 2016 Oct; 7(43):69371-69383. PubMed ID: 27750220
[TBL] [Abstract][Full Text] [Related]
6. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
7. Regulation of cytokine-driven functional differentiation of CD8 T cells by suppressor of cytokine signaling 1 controls autoimmunity and preserves their proliferative capacity toward foreign antigens.
Ramanathan S; Dubois S; Gagnon J; Leblanc C; Mariathasan S; Ferbeyre G; Rottapel R; Ohashi PS; Ilangumaran S
J Immunol; 2010 Jul; 185(1):357-66. PubMed ID: 20519645
[TBL] [Abstract][Full Text] [Related]
8. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
9. T cells: CiShh..
Bird L
Nat Rev Immunol; 2015 Dec; 15(12):728-9. PubMed ID: 26603898
[No Abstract] [Full Text] [Related]
10. Suppressor of cytokine signaling 3 regulates CD8 T-cell proliferation by inhibition of interleukins 6 and 27.
Brender C; Tannahill GM; Jenkins BJ; Fletcher J; Columbus R; Saris CJ; Ernst M; Nicola NA; Hilton DJ; Alexander WS; Starr R
Blood; 2007 Oct; 110(7):2528-36. PubMed ID: 17609432
[TBL] [Abstract][Full Text] [Related]
11. Galectin-1 tunes TCR binding and signal transduction to regulate CD8 burst size.
Liu SD; Tomassian T; Bruhn KW; Miller JF; Poirier F; Miceli MC
J Immunol; 2009 May; 182(9):5283-95. PubMed ID: 19380775
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.
Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Kammula US
Cancer Res; 2015 Aug; 75(16):3216-26. PubMed ID: 26100671
[TBL] [Abstract][Full Text] [Related]
13. Regulation of IL-21 signaling by suppressor of cytokine signaling-1 (SOCS1) in CD8(+) T lymphocytes.
Gagnon J; Ramanathan S; Leblanc C; Ilangumaran S
Cell Signal; 2007 Apr; 19(4):806-16. PubMed ID: 17126530
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
15. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
16. Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy.
Drakes DJ; Rafiq S; Purdon TJ; Lopez AV; Chandran SS; Klebanoff CA; Brentjens RJ
Cancer Immunol Res; 2020 Jun; 8(6):743-755. PubMed ID: 32209638
[TBL] [Abstract][Full Text] [Related]
17. K33-linked polyubiquitination of Zap70 by Nrdp1 controls CD8(+) T cell activation.
Yang M; Chen T; Li X; Yu Z; Tang S; Wang C; Gu Y; Liu Y; Xu S; Li W; Zhang X; Wang J; Cao X
Nat Immunol; 2015 Dec; 16(12):1253-62. PubMed ID: 26390156
[TBL] [Abstract][Full Text] [Related]
18. Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs.
Song S; Wang Y; Wang J; Lian W; Liu S; Zhang Z; Liu F; Wei L
Eur J Cancer; 2012 Sep; 48(14):2252-9. PubMed ID: 22230748
[TBL] [Abstract][Full Text] [Related]
19. High-avidity T cells are preferentially tolerized in the tumor microenvironment.
Zhu Z; Singh V; Watkins SK; Bronte V; Shoe JL; Feigenbaum L; Hurwitz AA
Cancer Res; 2013 Jan; 73(2):595-604. PubMed ID: 23204239
[TBL] [Abstract][Full Text] [Related]
20. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.
Kondo K; Fujiki F; Nakajima H; Yatsukawa E; Morimoto S; Tatsumi N; Nishida S; Nakata J; Oka Y; Tsuboi A; Hosen N; Oji Y; Sugiyama H
J Immunother; 2016 Apr; 39(3):127-39. PubMed ID: 26938946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
